Profound Medical PROF

Profound Medical introduces new real-time interventional MRI software enabling full 'TULSA Days' for its prostate treatment procedures. New software directly upgrades core TULSA technology and supports broader procedure adoption.

Profound Medical held Q2 2026 earnings call covering financial results, operations and outlook. Earnings call discloses quarterly results and guidance that can shift near-term sentiment and valuation.

Profound Medical Corp reported record orders in its Q2 2026 earnings call, indicating strong product demand and operational growth. Record orders signal major revenue growth potential and improved competitive positioning for Profound Medical.

Profound Medical Corp. conducted its Q2 2026 earnings call covering financial results, operational updates, and strategic outlook. Executives addressed revenue performance, product progress, and market positioning for the period. Earnings call delivers quarterly metrics and guidance that can shift near-term investor sentiment without altering core trajectory.

Profound Medical reported Q2 financial results and operational updates in its earnings call, covering revenue, product progress, and strategic outlook. Q2 earnings call delivered standard financial and operational updates with moderate potential to sway short-term investor sentiment.

Profound Medical reported Q2 earnings that surpassed estimates. Beating quarterly earnings estimates signals positive short-term results but rarely shifts long-term trajectory or competitive position.

Profound Medical reported second quarter 2026 financial results. Quarterly financial results typically influence short-term investor sentiment and valuation without guaranteeing long-term trajectory shifts.

CAPTAIN Trial shows robotic radical prostatectomy underperforms, potentially favoring non-invasive alternatives from Profound Medical in prostate cancer treatment. Trial outcome on competing surgical approach may moderately shift market sentiment toward Profound Medical offerings.

Profound Medical released Q1 earnings call highlights covering financial results, operational updates, and future outlook. Q1 earnings call highlights deliver key financial metrics, guidance, and strategic insights that significantly shape investor expectations and stock performance.

Profound Medical (PROF) shares fell 8.5% after hours despite Q1 results showing a narrowed loss and revenue more than doubling, beating analyst estimates. Revenue more than doubling and beating estimates with a narrowed loss signals significant growth momentum despite the after-hours selloff.

Profound Medical reported strong financial results for the first quarter of 2026. Strong Q1 2026 results highlight robust financial performance likely to boost investor confidence and future market trajectory.

Profound Medical Corp. (TSE:PRN) is expected to breakeven in the near future. Anticipated breakeven signals a major shift to profitability, significantly boosting future performance and investor sentiment.

Profound Medical showcased TULSA procedure data, AI software upgrades, and reimbursement tailwinds at a conference. Showcasing clinical data, AI enhancements, and reimbursement progress positions Profound Medical for significant adoption and revenue growth.

Profound Medical's TULSA-PRO, an incision-free MRI-guided prostate treatment, will be featured in multiple presentations at the 2026 Society of Interventional Radiology Scientific Meeting. Presentations at a major interventional radiology meeting enhance TULSA-PRO's visibility and credibility, moderately impacting competitive positioning and market sentiment.

Profound Medical announces CAPTAIN trial successfully met primary safety endpoint. Meeting primary safety endpoint in CAPTAIN trial represents major clinical progress enhancing regulatory pathways and investor sentiment for Profound Medical.

Profound Medical's CAPTAIN Trial successfully met its primary safety endpoint by preserving erectile function and urinary continence in patients treated with the MRI-Guided TULSA Procedure compared to robotic radical prostatectomy. Meeting primary safety endpoint in head-to-head trial against standard robotic prostatectomy validates TULSA's safety, potentially driving adoption and improving competitive positioning.

Profound Medical to host investor call on March 13 discussing first clinical outcomes from the CAPTAIN Trial; will participate in ROTH Investor Conference March 22-24. First clinical outcomes from the CAPTAIN Trial represent a major milestone that could significantly boost investor sentiment and alter the company's market trajectory.

Profound Medical Corp (PROF) Q4 2025 earnings call highlights revenue surge and strategic initiatives driving growth. Revenue surge and strategic moves indicate major positive shifts in financials and positioning for Profound Medical.

Profound Medical released Q4 earnings call highlights detailing financial performance, operational updates, and forward guidance. Q4 earnings highlights disclose annual financial results, pipeline progress, and outlook, poised to drive substantial shifts in valuation and market perception.

Profound Medical (PROF) reported a Q4 loss and missed revenue estimates. Q4 loss and revenue miss highlight weaker financial performance, moderately impacting investor sentiment and stock trajectory.

Profound Medical reported fourth quarter and full year 2025 financial results, detailing revenue, expenses, cash position, and operational highlights. Financial results for Q4 and full year directly affect assessments of revenue growth, profitability, and future guidance.

Profound Medical (PROF) Q4 earnings expected to decline. Expected Q4 earnings decline will moderately affect financial performance and investor sentiment.

Profound Medical has been awarded the 2025–2026 Mount Logan Award by INOVAIT, recognizing the TULSA Procedure™ for its innovative approach to treating prostate disease. This accolade highlights the procedure's significance in advancing medical technology and improving patient outcomes in prostate care. Recognition from INOVAIT signifies a major endorsement of the TULSA Procedure™, likely enhancing market position and investor confidence.

PRO FAMILIA and Profound Medical have celebrated the completion of 500 Sonalleve® procedures, marking a significant milestone in expanding access to incision-free care for women's health. This achievement highlights the growing adoption of the Sonalleve® technology, which offers a non-invasive treatment option for various gynecological conditions, thereby enhancing patient care and accessibility. The milestone of 500 procedures indicates significant market acceptance and potential for future growth in women's health treatments.

Profound Medical (PROF) has announced its participation in upcoming investor events, including the 2023 Canaccord Genuity Medical Technology & Diagnostics Forum and the 2023 Jefferies Healthcare Conference. These events provide opportunities for the company to engage with investors and discuss its innovative technologies and market strategies. The presentations will focus on the company's advancements in ultrasound-guided therapies and its growth potential in the medical technology sector. Participation in investor events can enhance visibility and investor sentiment, potentially influencing market performance.

Profound Medical (TSE:PRN) has seen a significant decline in its stock value, with investors losing 67% over the past five years. The company's performance has raised concerns among shareholders, reflecting broader challenges in the market and potential issues within the company's operations. The substantial loss in stock value indicates a moderately noticeable influence on the company's financial performance and investor sentiment.

Profound Medical (PROF) shares surged by 9.5%, driven by positive market sentiment and potential growth prospects. Investors are speculating on the stock's future performance, considering recent developments and the company's strategic direction. Analysts are evaluating whether this upward trend will continue, assessing factors that could influence the stock's trajectory in the coming months. The stock's recent surge indicates moderate investor interest, but the overall impact on long-term performance remains uncertain.

Mount Sinai has become the first medical institution in Metro New York to offer incision-free, MRI-guided prostate treatment using the TULSA-PRO® system. This innovative technology allows for precise targeting of prostate tissue while minimizing damage to surrounding areas, enhancing patient recovery and comfort. The introduction of TULSA-PRO® at Mount Sinai marks a significant advancement in prostate cancer treatment options available in the region. The introduction of TULSA-PRO® at a major medical center represents a significant advancement in treatment options, likely enhancing Profound Medical's market position and investor sentiment.

Profound Medical has exceeded its goal for the installed base of TULSA-PRO® systems by 2025, achieving significant growth in its market presence. The company reported a notable increase in installations, reflecting strong demand for its innovative prostate cancer treatment technology. This milestone underscores Profound's commitment to expanding its footprint in the medical device sector and enhancing patient care options. Exceeding installation goals indicates strong market demand and potential for significant future revenue growth.

Johns Hopkins Medicine has successfully performed its first commercial TULSA-PRO® procedure, a significant milestone for Profound Medical. This innovative technology offers a non-invasive treatment option for prostate cancer, enhancing patient care and expanding the market presence of Profound Medical. The procedure's success at a prestigious institution like Johns Hopkins is expected to bolster confidence in the TULSA-PRO® system and potentially lead to increased adoption in other medical facilities. The successful implementation of TULSA-PRO® at a leading medical institution is likely to significantly enhance market adoption and investor sentiment.